Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-27
2008-10-21
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S012200, C514S054000, C530S350000, C424S009100, C435S069100, C435S320100, C435S252300, C536S023500
Reexamination Certificate
active
07439224
ABSTRACT:
The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and/or treatment of infection. In particular the invention relates to prophylaxis and/or treatment of infection in an individual having an immunocompromised condition; and/or an individual being at risk of acquiring an immunocompromised condition resulting from a medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of infection in individuals suffering from neutropenia, in particular as prophylaxis and/or treatment of infection in individuals receiving or going to receive chemotherapy or similar treatment. The individuals may be treated independent on their serum MBL level, and it has been shown that in particular individuals having a serum MBL level in the range of from 50 ng/ml serum to 500 ng/ml serum may benefit from the prophylaxis and/or treatment.
REFERENCES:
patent: 5112952 (1992-05-01), Mallia et al.
patent: 5270199 (1993-12-01), Ezekowitz
patent: 7202207 (2007-04-01), Thiel et al.
patent: 0856580 (1998-08-01), None
patent: 8901519 (1989-02-01), None
patent: 9910001 (1999-03-01), None
patent: 9964453 (1999-12-01), None
Yokota, et al., “Oligomeric Structures Required for Complement Activation of Serum Mannan-Binding Proteins,”J. Biochem. 117:414-419 (1995).
Weis, et al., “The C-type Lectin Superfamily in the Immune System,”Immunological Reviews163:19-34 (1998).
Holmskov, et al., “Collectins: Collegenous C-type Lectins of the Innate Immune Defense System,”Immunology Today15(2): 67-74 (1994).
Turner, “Mannose-binding Lectin: the Pluripotent Molecule of the Innate Immune System,”Immunology Today17(11):532-540 (1996).
Janeway, et al., “Immunobiology, The Immune System in Health and Disease,” Fourth Edition, Churchill Livingston (1999).
Matsushita, et al., “Activation of the Classical Complement Pathway by Mannose-binding Protein in Association with a Novel C1s-like Serine Protease,”J. Exp. Med.176:1497-1502 (1992).
Thiel, et al., “A Second Serine Protease Associated with Mannan-binding Lectin that Activates Complement,”Nature386:506-510 (1997).
Stover, et al., “Two Constituents of the Initiation Complex of the Mannan-Binding Lectin Activation Pathway of Complement are Encoded by a Single Structure Gene,”The Journal of Immunology162:3481-3490 (1999).
Holmskov, et al., “The Concentration of the C-type Lectin, Mannan-binding Protein, in Human Plasma Increases During an Acute Phase Response,”Clin. Exp. Immunol.90:31-35 (1992).
Madsen, et al., “A New Frequent Alieie is the Missing Link in the Structural Polymorphism of the Human Mannan-binding Protein,”Immunogenetics40:37-44 (1994).
Summerfield, et al., “Mannose Binding Protein Gene Mutations Associated with Unusual and Severe Infections in Adults,”The Lancet345:886-889 (1995).
Garred, et al., “Increased Frequency of Homozygosity of Abnormal Mannan-binding-protein-Alleles in Patients with Suspected Immunodeficiency,”The Lancet346:941-943 (1995).
Summerfield, et al., “Association of Mutations in Mannose Binding Protein Gene with Childhood Infection in Consecutive Hospital Series,”BMJ314:1229-1232 (1997).
Emmerik, et al., “Binding of Mannan-Binding Protein to Various Bacterial Pathogens of Meningitis,”Clin. Exp. Immunol.97:411-416 (1994).
Jack, et al., “Activation of Complement by Mannose-Binding Lectin on Isogenic Mutants ofNeisseria meningitidisSerogroup B,”The Journal of Immunology160:1346-1353 (1998).
Miller, et al., “A Familial, Plasma-associated Defect of Phagocytosis,”The Lancetpp. 60-63 (1968).
Super, et al., “Association of Low Levels of Mannan-binding Protein with a Common Defect of Opsonisation,”The Lancet2:1236-1239 (1989).
Nielsen, et al., “The Level of the Serum Opsonin, Mannan-binding Protein in HIV-1 Antibody-Positive Patients,”Clin. Exp. Immunol.100:219-222 (1995).
Christiansen, et al., “Mannan-binding Lectin Deficiency is Associated with Unexplained Recurrent Miscarriage,”Scand. J. Immunol.49:193-196 (1999).
Garred, et al., “Dual Role of Mannan-binding Protein in Infections: Another Case of Heterosis?, ”European Journal of Immunogenetics21:125-131 (1994).
Hoal-van Helden, et al., “Mannose-Binding Protein B Allele Confers Protection Against Tuberculous Meningitis,”Pediatric Research45(4):459-464 (1999).
Fischer, et al., “Mannan-Binding Protein and Bovine Conglutinin Mediate Enhancement of Herpes Simplex Virus Type 2 Infection in Mice,”Scand. J. Immunol.39:439-445 (1994).
Valdimarsson, et al., “Reconstruction of Opsonizing Activity by Infusion of Mannan-Binding Lectin (MBL) to MBL-Deficient Humans,”Scand. J. Immunol.48:116-123 (1998).
Pizzo, “Drug Therapy: Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia,”The New England Journal of Medicine328(18):1323-1332 (1993).
Aittoniemi, et al., “Opsonising Immunoglobulins and Mannan-Binding Lectin in Chronic Lymphocytic Leukemia,”Leukemia and Lymphoma34(3-4):381-385 (1999).
Lehrnbecher, et al., “Assessment of Measuring Circulating Levels of Interleukin-6, Interleukin-8, C-Reactive Protein, Soluble Fcγ Receptor Type III, and Mannose-Binding Protein in Febrile Children with Cancer and Neutropenia,”Clinical Infectious Diseases29:414-419 (1999).
Lu, et al., “Binding of the Pentamer/Hexamer Forms of Mannan-Binding Protein to Zymosan Activities the Proenzyme Clr2CIS2Complex, of the Classical Pathway of Compiement, without Involvement of Clq,”The Journal of Immunology144:2287-2294 (1990).
Sastry, et al., “Exon Structure Reveals its Evolutionary Relationship to a Human Pulmonary Surfactant Gene and Localization to Chromosome 10, ”J. Exp. Med.170:1175-1189 (1989(.
Lipscombe, et al., “Distinct Physicochemical Characteristics of Human Mannose Binding Protein Expressed by Individuals of Differing Genotype,”Immunology85:660-667 (1995).
Makrides, “Components of Vectors for Gene Transfer and Expression in Mammalian Cells,”Protein Expression and Purification17:183-202 (1999).
Jensenius Jens Christian
Thiel Steffen
Cooper Iver P.
Kam Chih-Min
LandOfFree
Indications of mannan-binding lectin (MBL) in the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indications of mannan-binding lectin (MBL) in the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indications of mannan-binding lectin (MBL) in the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3996881